Myriad Posts 21 Percent Revenue Growth for Q3 | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its third-quarter revenues increased 21 percent year over year, with sales of the firm's BART test jumping nearly 400 percent.

The Salt Lake City-based molecular diagnostics company brought in total revenues of $156.5 million for the three months ended March 31, compared to $129.8 million for the third quarter of 2012. It beat the consensus Wall Street estimate for revenues of $148.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.